帕利哌酮缓释片与奥氮平治疗精神分裂症的对照研究  

Control study of Paliperidone Extended Release Tablets and Olanzapine for schizophrenia

作　　者：瞿波[1] 韩红[1] 侯敏[1] 

机构地区：[1]泸州医学院附属医院精神科,四川泸州646000

出　　处：《实用医院临床杂志》2012年第3期77-78,共2页Practical Journal of Clinical Medicine

摘　　要：目的对比帕利哌酮与奥氮平治疗精神分裂症的效果。方法将70例精神分裂症患者按随机数字表法分为帕利哌酮缓释剂组和奥氮平组各35例。入组前未用抗精神病药物或停用抗精神病药物2周以上,分别使用帕利哌酮缓释剂和奥氮平治疗,疗程均为8周。两组均采用阳性与阴性症状量表(PANSS)评定疗效,同时采用副反应量表(TESS)评定不良反应。结果两组疗效均显著,组间比较差异无统计学意义(P>0.05);帕利哌酮缓释剂组主要不良反应为椎体外系副反应(EPS)、焦虑等,奥氮平组主要不良反应为心动过速、嗜睡等;帕利哌酮缓释剂组EPS、失眠、焦虑发生率明显高于奥氮平组(P<0.05),心动过速、便秘、嗜睡、唾液增多明显低于奥氮平组(P<0.05)。结论帕利哌酮可作为精神分裂症的一线用药和维持治疗用药。Objective To compare the treatment effect of Paliperidone Extended-Release Tablets and Olanzapine for schizophrenia. Methods We randomly divided 70 schizophrenics（free of antipsychotics for more than 2 weeks） into two groups（35 cases in each group）.One was treated with Paliperidone Extended-Release Tablets,the other with Olanzepine for 8 weeks.We assessed the curative effect of the two groups by Scale for the Assessment of Positive Symptoms and Scale for the Assessment of Negative Symptoms,and assessed the adverse reaction by the Side Effects Scale. Results There was no significant difference between the two groups in the treatment effect（P 0.05）.The adverse reaction of Paliperidone Extended-Release Tablets included extrapyramidal side effect（EPS）,anxiety and so on.The adverse reaction of Olanzepine included tachycardia,somnolence,and saliva increase and so on.The incidence of EPS,somnolence and anxiety in patients with Paliperidone Extended-Release Tablets was significantly higher than that in those with Olanzapine（P 0.05）. Conclusions Paliperidone Extended-Release Tablets can be used in the first-line treatment and the maintenance treatment of schizophrenic.

关 键 词：帕利哌酮缓释剂 奥氮平 精神分裂症 

分 类 号：R971.4[医药卫生—药品] R749.3[医药卫生—药学]